Brain cancer breakthrough? new drug combo hits tough tumors
NCT ID NCT03961971
Summary
This early-stage trial is testing whether combining two immunotherapy drugs with a precise, high-dose radiation treatment is safe and might help control recurrent glioblastoma, a very aggressive brain cancer. The study involves about 16 patients whose cancer has returned after initial treatment. Researchers want to see if this three-part approach can better target the cancer and help the immune system fight it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Stanford University
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.